Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer

Recruiting now

Conditions studied: Prostate Cancer, Adaptive Radiotherapy, Quality of Life

In brief

In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany. Radiotherapy is delivered by an online-adaptive RT device (Varian Ethos), which is able to correct daily variations in anatomy and to adjust the irradiation plan accordingly. A digital patient questionnaire is used to asses quality of life longitudinally. Quality of life (QoL) and toxicity profiles will be correlated with planning parameters and compared to retrospective cohorts of patients who underwent normofractionated RT or moderately hypofractionated RT, respectively.

Key facts

Study ID

NCT06355050

Run by

Jena University Hospital

People needed

150

Starts

2026-04-01

Expected to finish

2032-09-30

Last updated by the study team

2026-06-11

Who can join

Age: 18 and older, up to 120. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• no androgen deprivation therapy within the last 2 months prior to RT
• good performance status (Eastern Cooperative Oncology Group, ECOG, 0/1)
• no secondary malignancy

Where it is running

• Department of Radiotherapy and Radiation Oncology, Jena University Hospital — Jena, Germany (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.